SANTEN PHARMACEUTICAL CO.,LTD. Logo

SANTEN PHARMACEUTICAL CO.,LTD.

A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.

4536 | T

Overview

Corporate Details

ISIN(s):
JP3336000009
LEI:
Country:
Japan
Address:
大阪市北区大深町4番20号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santen Pharmaceutical Co., Ltd. is a global pharmaceutical company specializing in ophthalmology. The company engages in the research, development, manufacturing, sales, and marketing of pharmaceutical products and medical devices dedicated to eye health. Its portfolio addresses a wide range of ocular conditions, including glaucoma, dry eye, and infections. Serving patients, consumers, and medical professionals, Santen operates in over 60 countries and regions worldwide, guided by its vision of contributing to "Happiness with Vision" for people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 07:02
Registration Form
確認書
Japanese 8.7 KB
2025-11-10 07:01
Interim Report
半期報告書-第114期(2025/04/01-2026/03/31)
Japanese 366.6 KB
2025-10-15 03:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-09-12 04:58
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.9 KB
2025-08-13 03:24
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-15 04:38
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-25 04:08
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-24 09:22
Remuneration Information
臨時報告書
Japanese 32.1 KB
2025-06-23 08:29
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-23 08:28
Registration Form
確認書
Japanese 8.5 KB
2025-06-23 08:27
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 2.2 MB
2025-06-13 04:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-04-15 06:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB
2025-03-13 03:29
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.8 KB
2025-02-14 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB

Automate Your Workflow. Get a real-time feed of all SANTEN PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SANTEN PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SANTEN PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.